Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand.
Journal
Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
accepted:
20
06
2023
medline:
23
8
2023
pubmed:
9
8
2023
entrez:
9
8
2023
Statut:
ppublish
Résumé
In February 2021, New Zealand began its largest ever immunisation programme with the BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine. We aimed to understand the association between 12 adverse events of special interest (AESIs) and a primary dose of BNT162b2 in the New Zealand population aged ≥5 years from 19 February 2021 through 10 February 2022. Using national electronic health records, the observed rates of AESIs within a risk period (1-21 days) following vaccination were compared with the expected rates based on background data (2014-2019). Standardised incidence ratios (SIRs) were estimated for each AESI with 95% confidence intervals (CIs) using age group-specific background rates. The risk difference was calculated to estimate the excess or reduced number of events per 100,000 persons vaccinated in the risk period. As of 10 February 2022, 4,277,163 first doses and 4,114,364 second doses of BNT162b2 had been administered to the eligible New Zealand population aged ≥5 years. The SIRs for 11 of the 12 selected AESIs were not statistically significantly increased post vaccination. The SIR (95% CI) for myo/pericarditis following the first dose was 2.3 (1.8-2.7), with a risk difference (95% CI) of 1.3 (0.9-1.8), per 100,000 persons vaccinated, and 4.0 (3.4-4.6), with a risk difference of 3.1 (2.5-3.7), per 100,000 persons vaccinated following the second dose. The highest SIR was 25.6 (15.5-37.5) in the 5-19 years age group, following the second dose of the vaccine, with an estimated five additional myo/pericarditis cases per 100,000 persons vaccinated. A statistically significant increased SIR of single organ cutaneous vasculitis (SOCV) was also observed following the first dose of BNT162b2 in the 20-39 years age group only. A statistically significant association between BNT162b2 vaccination and myo/pericarditis was observed. This association has been confirmed internationally. BNT162b2 was not found to be associated with the other AESIs investigated, except for SOCV following the first dose of BNT162b2 in the 20-39 years age group only, providing reassurances around the safety of the vaccine.
Identifiants
pubmed: 37556109
doi: 10.1007/s40264-023-01332-1
pii: 10.1007/s40264-023-01332-1
pmc: PMC10442303
doi:
Substances chimiques
BNT162 Vaccine
0
COVID-19 Vaccines
0
RNA, Messenger
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
867-879Informations de copyright
© 2023. The Author(s).
Références
Ministry of Health New Zealand. COVID-19: Vaccines. 2022. https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-vaccines . Accessed 24 Jan 2022.
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577 .
doi: 10.1056/NEJMoa2034577
pubmed: 33301246
Ministry of Health New Zealand. COVID-19 vaccines available in New Zealand. 2022. https://www.health.govt.nz/covid-19-novel-coronavirus/covid-19-vaccines/covid-19-vaccines-available-new-zealand . Accessed 5 Apr 2022.
Medsafe. COVID-19. Status of Application. Comirnaty (Pfizer-BioNTech): 12 years and older 2022. https://www.medsafe.govt.nz/COVID-19/status-of-applications.asp#Comirnaty12 . Accessed 7 Feb 2022.
Medsafe. COVID-19. Status of Application. Comirnaty (Pfizer-BioNTech): 5 years and older 2022. https://www.medsafe.govt.nz/COVID-19/status-of-applications.asp#Comirnaty5 . Accessed 7 Feb 2022.
Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. 2020. https://doi.org/10.1177/2042098620938595 .
doi: 10.1177/2042098620938595
pubmed: 32843958
pmcid: 7418468
Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA vaccines. Circulation. 2021;144(6):471–84. https://doi.org/10.1161/CIRCULATIONAHA.121.056135 .
doi: 10.1161/CIRCULATIONAHA.121.056135
pubmed: 34281357
pmcid: 8340726
Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078–90. https://doi.org/10.1056/NEJMoa2110475 .
doi: 10.1056/NEJMoa2110475
pubmed: 34432976
Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021;385(23):2140–9. https://doi.org/10.1056/NEJMoa2109730 .
doi: 10.1056/NEJMoa2109730
pubmed: 34614328
Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 vaccination in a large health care organization. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2110737 .
doi: 10.1056/NEJMoa2110737
pubmed: 34614329
pmcid: 8531986
Boehmer TK, Kompaniyets L, Lavery AM, et al. Association between COVID-19 and myocarditis using hospital-based administrative data—United States, March 2020–January 2021. Morb Mortal Wkly Rep. 2021;70(35):1228. https://doi.org/10.15585/mmwr.mm7035e5 .
doi: 10.15585/mmwr.mm7035e5
Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. 2022;28(2):410–22. https://doi.org/10.1038/s41591-021-01630-0 .
doi: 10.1038/s41591-021-01630-0
pubmed: 34907393
Harpaz R, DuMouchel W, Van Manen R, et al. Signaling COVID-19 vaccine adverse events. Drug Saf. 2022;45(7):765–80. https://doi.org/10.1007/s40264-022-01186-z .
doi: 10.1007/s40264-022-01186-z
pubmed: 35737293
pmcid: 9219360
New Zealand Data Sheet. Comirnaty Concentrate for injection (orange cap, must dilute) 10 mcg/0.2 mL dose. 2021. https://www.medsafe.govt.nz/profs/Datasheet/c/Comirnaty0.2mlOrangeCapinj.pdf . Accessed 19 Mar 2022.
World Health Organisation. COVID-19 vaccines: safety surveillance manual. World Health Organization. License: CC BY-NC-SA 3.0 IGO 2020; Available from: https://apps.who.int/iris/handle/10665/338400 .
Medsafe. COVID-19- Safety Monitoring. November 27, 2020. https://www.medsafe.govt.nz/COVID-19/medicine-safety-monitoring.asp . Accessed 7 Feb 2022.
Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health. 1995;85(12):1706–9. https://doi.org/10.2105/ajph.85.12.1706 .
doi: 10.2105/ajph.85.12.1706
pubmed: 7503351
pmcid: 1615747
StatsNZ. Taturanga Aotearoa. New Zealand's population reflects growing diversity. 23 September 2019. https://www.stats.govt.nz/news/new-zealands-population-reflects-growing-diversity . Accessed 5 Apr 2022.
Baker MG, Wilson N, Anglemyer A. Successful elimination of Covid-19 transmission in New Zealand. N Engl J Med. 2020;383(8): e56. https://doi.org/10.1056/NEJMc2025203 .
doi: 10.1056/NEJMc2025203
pubmed: 32767891
Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Pharmacoepidemiol Drug Saf. 2016;25(2):215. https://doi.org/10.1002/pds.3918 .
doi: 10.1002/pds.3918
pubmed: 26602179
Ministry of Health New Zealand. NZ Health System. Guide to eligibility for publicly funded health services. 26 January 2022. https://www.health.govt.nz/new-zealand-health-system/eligibility-publicly-funded-health-services/guide-eligibility-publicly-funded-health-services . Accessed 2 Mar 2022.
Ministry of Health New Zealand. Health Statistics. National Minimum Dataset (hospital events). 15 June 2021. https://www.health.govt.nz/nz-health-statistics/national-collections-and-surveys/collections/national-minimum-dataset-hospital-events . Accessed 2 Mar 2022.
Ministry of Health New Zealand. COVID-19 Vaccines- Your Privacy- COVID Immunisation Register (CIR) privacy statement. 2021. https://www.health.govt.nz/our-work/diseases-and-conditions/covid-19-novel-coronavirus/covid-19-vaccines/covid-19-vaccine-and-your-privacy/covid-immunisation-register-cir-privacy-statement . Accessed 10 Feb 2022.
The Ministry of Health New Zealand. Media releases. Free rapid antigen tests now available for home testing. 2 March 2022. https://www.health.govt.nz/news-media/media-releases/free-rapid-antigen-tests-now-available-home-testing . Accessed 5 Apr 2022.
COVID-19 GOVT NZ. Get your second dose. 2022. https://covid19.govt.nz/covid-19-vaccines/how-to-get-a-covid-19-vaccination/getting-your-second-dose . Accessed 11 Mar 2022.
Stats NZ. Tatauranga Aotearoa. Migration. https://www.stats.govt.nz/topics/migration . Accessed 1 Jun 2023.
Global Vaccine Data Network. SAFE Project: Background rates of adverse events of special interest (AESIs) for COVID-19 vaccination. https://www.globalvaccinedatanetwork.org/safe-project-background-rates-adverse-events-special-interest-aesis-covid-19-vaccination . Accessed 13 Feb 2023.
Brighton Collaboration. Safety Platform for Emergency VACcines (SPEAC). Priority List of Adverse Events of Special Interest: COVID-19. V2.0 May 25, 2020. https://brightoncollaboration.us/wp-content/uploads/2020/06/SPEAC_D2.3_V2.0_COVID-19_20200525_public.pdf . Accessed 10 Feb 2022.
Willame C, Dodd C, Durán C, et al. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases-an ACCESS cohort study. Vaccine. 2023;41(1):251–62. https://doi.org/10.1016/j.vaccine.2022.11.031 .
doi: 10.1016/j.vaccine.2022.11.031
pubmed: 36446653
Ministry of Health New Zealand. Health Statistics. ICD-10AM/ACH1/ACS Development 11 August 2021. https://www.health.govt.nz/nz-health-statistics/classification-and-terminology/icd-10-am-achi-acs/icd-10-am-achi-acs-development . Accessed 5 Apr 2022.
Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021;326(14):1390–9. https://doi.org/10.1001/jama.2021.15072 .
doi: 10.1001/jama.2021.15072
pubmed: 34477808
Naing NN. Easy way to learn standardization: direct and indirect methods. Malays J Med Sci. 2000;7(1):10.
pubmed: 22844209
pmcid: 3406211
Breslow NE, Day N. Indirect standardization and multiplicative models for rates, with reference to the age adjustment of cancer incidence and relative frequency data. J Chronic Dis. 1975;28(5–6):289–303. https://doi.org/10.1016/0021-9681(75)90010-7 .
doi: 10.1016/0021-9681(75)90010-7
pubmed: 1141424
Flowers-Cano RS, Ortiz-Gómez R, León-Jiménez JE, et al. Comparison of bootstrap confidence intervals using monte carlo simulations. Water. 2018;10(2):166. https://doi.org/10.3390/w10020166 .
doi: 10.3390/w10020166
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2021; Available from: http://www.R-project.org/ .
Arola A, Pikkarainen E, Sipilä JO, et al. Occurrence and features of childhood myocarditis: a nationwide study in Finland. J Am Heart Assoc. 2017;6(11): e005306. https://doi.org/10.1161/JAHA.116.005306 .
doi: 10.1161/JAHA.116.005306
pubmed: 29151030
pmcid: 5721735
Block JP. Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination—PCORnet, United States, January 2021–January 2022. MMWR. Morbidity and Mortality Weekly Report, 2022. 71.
Medsafe. Safety information. Alert communication. Myocarditis and Pericarditis - rare adverse reactions to Comirnaty (Pfizer COVID-19 vaccine). 21 July 2021. https://medsafe.govt.nz/Safety/Alerts/comirnaty-myocarditis-alert.htm . Accessed 22 Feb 2022.
Abdelmaksoud A, Wollina U, Temiz SA, Hasan A. SARS-CoV-2 vaccination-induced cutaneous vasculitis: report of two new cases and literature review. Dermatol Ther. 2022;35(6): e15458. https://doi.org/10.1111/dth.15458 .
doi: 10.1111/dth.15458
pubmed: 35306713
pmcid: 9111803
Saleh AM, Khalid A, Alshaya AK and Alanazi SMM. Systemic lupus erythematosus with acute pancreatitis and vasculitic rash following COVID-19 vaccine: a case report and literature review. Clin Rheumatol. 2022;41(5):1577–82. https://doi.org/10.1007/s10067-022-06097-z
Baier E, Olgemoller U, Biggemann L, et al. Dual-positive MPO- and PR3-ANCA-associated vasculitis following SARS-CoV-2 mRNA booster vaccination: a case report and systematic review. Vaccines (Basel). 2022;10(5):653. https://doi.org/10.3390/vaccines10050653 .
doi: 10.3390/vaccines10050653
pubmed: 35632410
Ogura Y, Morimoto H, Otsuka M and Tokura Y. Development of IgA vasculitis after SARS‐CoV‐2 vaccination. J Cutaneous Immunol Allergy. 2022;5(5):190–1. https://doi.org/10.1002/cia2.12242
Simpson CR, Shi T, Vasileiou E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med. 2021;27(7):1290–7. https://doi.org/10.1038/s41591-021-01408-4 .
doi: 10.1038/s41591-021-01408-4
pubmed: 34108714
pmcid: 8282499
Abbattista M, Martinelli I, Peyvandi F. Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: thrombosis at unusual sites. J Thromb Haemost. 2021;19(10):2554–8. https://doi.org/10.1111/jth.15493 .
doi: 10.1111/jth.15493
pubmed: 34375510
Hviid A, Hansen JV, Thiesson EM, Wohlfahrt J. Association of AZD1222 and BNT162b2 COVID-19 Vaccination with thromboembolic and thrombocytopenic events in frontline personnel: a retrospective cohort study. Ann Intern Med. 2022;175(4):541–6. https://doi.org/10.7326/M21-2452 .
doi: 10.7326/M21-2452
pubmed: 35103482
Houghton DE, Wysokinski W, Casanegra AI, et al. Risk of venous thromboembolism after COVID-19 vaccination. J Thromb Haemost. 2022;20(7):1638–44. https://doi.org/10.1111/jth.15725 .
doi: 10.1111/jth.15725
pubmed: 35398975
pmcid: 9115120
Walton M, Tomkies R, Teunissen T, et al. Thrombotic events following the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) in Aotearoa New Zealand: a self-controlled case series study. Thromb Res. 2023;222:102–8. https://doi.org/10.1016/j.thromres.2022.12.012 .
doi: 10.1016/j.thromres.2022.12.012
pubmed: 36634464
Burn E, Li X, Delmestri A, et al. Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom. Nat Commun. 2022;13(1):7167. https://doi.org/10.1038/s41467-022-34668-w .
doi: 10.1038/s41467-022-34668-w
pubmed: 36418291
pmcid: 9684520
Burn E, Roel E, Pistillo A, et al. Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain. Nat Commun. 2022;13(1):7169. https://doi.org/10.1038/s41467-022-34669-9 .
doi: 10.1038/s41467-022-34669-9
pubmed: 36418321
pmcid: 9684434
Shroff H, Satapathy SK, Crawford JM, et al. Liver injury following SARS-CoV-2 vaccination: a multicenter case series. J Hepatol. 2022;76(1):211–4. https://doi.org/10.1016/j.jhep.2021.07.024 .
doi: 10.1016/j.jhep.2021.07.024
pubmed: 34339763
D’Agati VD, Kudose S, Bomback AS, et al. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine. Kidney Int. 2021;100(2):461–3. https://doi.org/10.1016/j.kint.2021.04.035 .
doi: 10.1016/j.kint.2021.04.035
pubmed: 34000278
pmcid: 8123374
Waheed S, Bayas A, Hindi F, et al. Neurological complications of COVID-19: Guillain-Barre syndrome following Pfizer COVID-19 vaccine. Cureus. 2021. https://doi.org/10.7759/cureus.13426 .
doi: 10.7759/cureus.13426
pubmed: 35047307
pmcid: 8760010
Rao SJ, Khurana S, Murthy G, et al. A case of Guillain-Barre syndrome following Pfizer COVID-19 vaccine. J Community Hosp Inter Med Pperspect. 2021;11(5):597–600. https://doi.org/10.1080/20009666.2021.1954284 .
doi: 10.1080/20009666.2021.1954284
Bonino CB, Arias NM, Rico MLP, et al. Atypical erythema multiforme related to BNT162b2 (Pfizer–BioNTech) COVID-19 vaccine. Int J Dermatol. 2021;60(11): e466. https://doi.org/10.1111/ijd.15894 .
doi: 10.1111/ijd.15894
Wong CKH, Mak LY, Au ICH, et al. Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) COVID-19 vaccines. J Hepatol. 2022;77(5):1339–48. https://doi.org/10.1016/j.jhep.2022.06.032 .
doi: 10.1016/j.jhep.2022.06.032
pubmed: 35817224
pmcid: 9376738
Li X, Raventós B, Roel E, et al. Association between covid-19 vaccination, SARS-CoV-2 infection, and risk of immune mediated neurological events: population based cohort and self-controlled case series analysis. BMJ. 2022. https://doi.org/10.1136/bmj-2021-068373 .
doi: 10.1136/bmj-2021-068373
pubmed: 36740855
pmcid: 9727920
Lai FTT, Chua GT, Chan EWW, et al. Adverse events of special interest following the use of BNT162b2 in adolescents: a population-based retrospective cohort study. Emerg Microb Infect. 2022;11(1):885–93. https://doi.org/10.1080/22221751.2022.2050952 .
doi: 10.1080/22221751.2022.2050952
Shasha D, Bareket R, Sikron FH, et al. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine: historical cohort study. Clin Microbiol Infect. 2022;28(1):130–4. https://doi.org/10.1016/j.cmi.2021.09.018 .
doi: 10.1016/j.cmi.2021.09.018
pubmed: 34592420
Birabaharan M, Kaelber DC, Karris MY. Risk of herpes zoster reactivation after messenger RNA COVID-19 vaccination: a cohort study. J Am Acad Dermatol. 2022;87(3):649–51. https://doi.org/10.1016/j.jaad.2021.11.025 .
doi: 10.1016/j.jaad.2021.11.025
pubmed: 34826538
Wan EYF, Chui CSL, Wang Y, et al. Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: a self-controlled case series and nested case-control study. Lancet Regional Health-Western Pacific. 2022;21: 100393. https://doi.org/10.1016/j.lanwpc.2022.100393 .
doi: 10.1016/j.lanwpc.2022.100393
pubmed: 35128500
pmcid: 8808060
Jefferies S, French N, Gilkison C, et al. COVID-19 in New Zealand and the impact of the national response: a descriptive epidemiological study. Lancet Public Health. 2020;5(11):e612–23. https://doi.org/10.1016/S2468-2667(20)30225-5 .
doi: 10.1016/S2468-2667(20)30225-5
pubmed: 33065023
pmcid: 7553903
Baker MG, Kvalsvig A, Crengle S, et al. The next phase in Aotearoa New Zealand’s COVID-19 response: a tight suppression strategy may be the best option. N Z Med J. 2021;134(1546):8–16.
pubmed: 34855729
Li X, Lai LY, Ostropolets A, et al. Bias, Precision and timeliness of historical (background) rate comparison methods for vaccine safety monitoring: an empirical multi-database analysis. Front Pharmacol. 2021;12: 773875. https://doi.org/10.3389/fphar.2021.773875 .
doi: 10.3389/fphar.2021.773875
pubmed: 34899334
pmcid: 8652333
Remschmidt C, Wichmann O, Harder T. Frequency and impact of confounding by indication and healthy vaccinee bias in observational studies assessing influenza vaccine effectiveness: a systematic review. BMC Infect Dis. 2015;15:1–15. https://doi.org/10.1186/s12879-015-1154-y .
doi: 10.1186/s12879-015-1154-y
Huang QS, Wood T, Jelley L, et al. Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. Nat Commun. 2021;12(1):1–7. https://doi.org/10.1038/s41467-021-21157-9 .
doi: 10.1038/s41467-021-21157-9
WHO - National influenza centres of the global influenza surveillance and response system. FluNet. https://www.who.int/tools/flunet . Accessed 5 Apr 2022.
Hills T, Hatter L, Kearns N, et al. COVID-19 border controls prevent a 2021 seasonal influenza epidemic in New Zealand. Public Health. 2021;200:e6–7. https://doi.org/10.1016/j.puhe.2021.09.013 .
doi: 10.1016/j.puhe.2021.09.013
pubmed: 34654573